Sign In
Buy ALPMY
$13.40
-0.200 (-1.47%)
At Close: Jun 03, 2026
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
03:59am, Wednesday, 05'th Feb 2025
- Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in Japan -
Astellas Makes Announcement about Management Structure
01:30am, Tuesday, 04'th Feb 2025
TOKYO , Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective
Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders
08:30pm, Wednesday, 25'th Dec 2024
TOKYO--(BUSINESS WIRE)-- #Astellas--Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders.
Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves
08:49am, Thursday, 05'th Dec 2024
"Cooler Moments" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives. NORTHBROOK, Ill.
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
01:00pm, Wednesday, 20'th Nov 2024
SAN FRANCISCO , Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DO
Should Value Investors Buy Astellas Pharma (ALPMY) Stock?
10:45am, Tuesday, 12'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Astellas: Can The Gastric Cancer Approval Be The Inflection Point?
12:04pm, Wednesday, 30'th Oct 2024
Astellas: Can The Gastric Cancer Approval Be The Inflection Point?
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
02:13pm, Friday, 18'th Oct 2024
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO , Oct. 18, 2
FDA approves Astellas' gastric cancer therapy
12:28pm, Friday, 18'th Oct 2024
The U.S. Food and Drug Administration approved Astellas' gastric cancer therapy, the health regulator's website showed on Friday.
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
03:00am, Thursday, 10'th Oct 2024
TOKYO , Oct. 10, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderat
Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development AviadoBio receives $20 million equity investment, up to $30 million in u
Are Investors Undervaluing Astellas Pharma (ALPMY) Right Now?
10:46am, Wednesday, 02'nd Oct 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Singlera Genomics and Astellas Present Methylation-based Organ Toxicity Detection at 2024 JSOT Annual Meeting
04:24pm, Tuesday, 01'st Oct 2024
SAN DIEGO--(BUSINESS WIRE)--Singlera Genomics and Astellas Pharma presented results during the JSOT 2024 Annual Meeting demonstrating that drug-induced testicular toxicity can be detected using cell-f
- Zolbetuximab is currently the first and only therapy approved in the European Union to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer1,2 - Tre
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
07:30pm, Wednesday, 18'th Sep 2024
- New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring - TOKYO , Sept. 18, 2024 /PRNewswire/ -- Astell
